Mr. Eric Offenberger reports

VEXT ANNOUNCES DELAY OF ANNUAL FILINGS AND POSTPONEMENT OF CONFERENCE CALL

Vext Science Inc.'s annual financial statements for the year ended Dec. 31, 2023, the related management's discussion and analysis, and officer certifications (collectively, the annual filings) are not expected to be filed by April 25, 2024, as originally anticipated, or by the required filing deadline of April 29, 2024. As a result of the expected delay in filing the annual filings, the company's previously announced conference call and webcast originally scheduled for April 25, 2024, at 8 a.m. ET is postponed until the annual filings are completed.

The annual filings are not expected to be filed on or before the filing deadline due to the company's recent change of auditor from BF Borgers CPA PC to Reliant CPA and the complex accounting treatment of certain transactions that occurred in Q4 of 2023. Q4 of 2023 was a very active quarter for Vext, with: the closing of the acquisition of Appalachian Pharm Processing LLC and related entities in Ohio; the signing of definitive agreements to acquire two additional Ohio dispensaries; the sale of the company's Prescott Valley cultivation facility; the closing of a private placement; and the signing of definitive agreements to exchange certain debt obligations for shares.

The company is working diligently with its accounting staff and external auditor to complete its annual filings and expects to be able to file the annual filings on or before May 10, 2024. Additionally, the company has applied to the applicable securities regulatory authorities for a management cease trade order (the MCTO), which, if granted, would restrict the company's chief executive officer and chief financial officer from trading in securities of the company, whether direct or indirect, until the annual filings are filed. There is no guarantee that an MCTO will be granted.

The company will provide updates as further information relating to the annual filings, the conference call and the MCTO becomes available. Until the annual filings are filed, the company intends to comply with the provisions of the alternative information guidelines as set out in National Policy 12-203 -- Management Cease Trade Orders for as long as the annual filings remain outstanding, including the issuance of bi-weekly default status reports in the form of a news release, if applicable.

About Vext Science Inc.

Vext Science is a United States-based cannabis operator with vertical operations in Arizona and Ohio. Vext's expertise spans from cultivation through to retail operations in its key markets. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The company manufactures Vapen, one of the leading THC concentrates, edibles and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio, as well as through Vext's partnerships in other states. Vext's leadership team brings a proven record of building and operating profitable multistate operations, with the company having operated profitably since 2016. The company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing and marketing to provide a reliable and valuable customer experience while generating shareholder value.

We seek Safe Harbor.